CU24130B1 - Isoquinolinonas y quinazolinonas sustituidas - Google Patents

Isoquinolinonas y quinazolinonas sustituidas

Info

Publication number
CU24130B1
CU24130B1 CU2012000098A CU20120098A CU24130B1 CU 24130 B1 CU24130 B1 CU 24130B1 CU 2012000098 A CU2012000098 A CU 2012000098A CU 20120098 A CU20120098 A CU 20120098A CU 24130 B1 CU24130 B1 CU 24130B1
Authority
CU
Cuba
Prior art keywords
isoquinolinones
quinazolinones
replaced
formula
mdm4
Prior art date
Application number
CU2012000098A
Other languages
English (en)
Other versions
CU20120098A7 (es
Inventor
Joerg Berghausen
Nicole Buschmann
Pascal Furet
Francois Gessier
Lisztwan Joanna Hergovich
Philipp Holzer
Edgar Jacoby
Joerg Kallen
Keiichi Masuya
Soldermann Carole Pissot
Haixia Ren
Stefan Stutz
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45093718&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU24130(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Priority claimed from PCT/EP2010/070364 external-priority patent/WO2011076786A1/en
Publication of CU20120098A7 publication Critical patent/CU20120098A7/es
Publication of CU24130B1 publication Critical patent/CU24130B1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La invención se refiere a heterociclos bicíclicos que contienen nitrógeno sustituidos de la fórmula (I): ESPACIO PARA LA FÓRMULA en donde Z es CH2 o N-R4, y X, R1, R2, R4, R6, R7 y n son como se definen en la descripción. Estos compuestos son adecuados para el tratamiento de un trastorno o enfermedad que sea mediada por la actividad de MDM2 y/o MDM4, o variantes de los mismos.
CU2012000098A 2009-12-22 2010-12-21 Isoquinolinonas y quinazolinonas sustituidas CU24130B1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28899209P 2009-12-22 2009-12-22
CN2010078927 2010-11-19
PCT/EP2010/070364 WO2011076786A1 (en) 2009-12-22 2010-12-21 Substituted isoquinolinones and quinazolinones

Publications (2)

Publication Number Publication Date
CU20120098A7 CU20120098A7 (es) 2012-10-15
CU24130B1 true CU24130B1 (es) 2015-09-29

Family

ID=45093718

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2012000098A CU24130B1 (es) 2009-12-22 2010-12-21 Isoquinolinonas y quinazolinonas sustituidas

Country Status (34)

Country Link
US (2) US9073898B2 (es)
EP (1) EP2640467B1 (es)
JP (1) JP5667308B2 (es)
KR (1) KR101561750B1 (es)
AR (1) AR083905A1 (es)
AU (1) AU2011331095B2 (es)
BR (1) BR112013011966A2 (es)
CA (1) CA2816810A1 (es)
CO (1) CO6801719A2 (es)
CU (1) CU24130B1 (es)
CY (1) CY1116002T1 (es)
DK (1) DK2640467T3 (es)
EC (1) ECSP13012628A (es)
ES (1) ES2528376T3 (es)
GT (1) GT201300132A (es)
HR (1) HRP20150231T1 (es)
IL (1) IL226182A0 (es)
MA (1) MA34666B1 (es)
ME (1) ME02099B (es)
MX (1) MX336634B (es)
MY (1) MY160880A (es)
NZ (1) NZ610296A (es)
PE (1) PE20140420A1 (es)
PH (1) PH12013500979A1 (es)
PL (1) PL2640467T3 (es)
PT (1) PT2640467E (es)
RS (1) RS53770B1 (es)
RU (1) RU2013127661A (es)
SG (1) SG190186A1 (es)
SI (1) SI2640467T1 (es)
SM (1) SMT201500059B (es)
TW (1) TWI520950B (es)
WO (1) WO2012066095A1 (es)
ZA (1) ZA201303155B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2118123T3 (pl) 2007-01-31 2016-06-30 Dana Farber Cancer Inst Inc Stabilizowane peptydy p53 i ich zastosowania
JP5631201B2 (ja) 2007-03-28 2014-11-26 プレジデント アンド フェローズ オブ ハーバード カレッジ ステッチングされたポリペプチド
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
KR102104762B1 (ko) 2010-08-13 2020-04-24 에일러론 테라퓨틱스 인코포레이티드 펩티도미메틱 거대고리
EP2768518A4 (en) 2011-10-18 2015-05-27 Aileron Therapeutics Inc PEPTIDOMIMETIC MACROCYCLES
US9408885B2 (en) * 2011-12-01 2016-08-09 Vib Vzw Combinations of therapeutic agents for treating melanoma
RU2642299C2 (ru) 2012-02-15 2018-01-24 Эйлерон Терапьютикс, Инк. P53 пептидомиметические макроциклы
CA2864120A1 (en) 2012-02-15 2013-08-22 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
JP6171003B2 (ja) 2012-05-24 2017-07-26 ノバルティス アーゲー ピロロピロリジノン化合物
BR112015009470A2 (pt) 2012-11-01 2019-12-17 Aileron Therapeutics Inc aminoácidos dissubstituídos e seus métodos de preparação e uso
US9556180B2 (en) 2013-01-22 2017-01-31 Novartis Ag Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the P53/MDM2 interaction
US9403827B2 (en) 2013-01-22 2016-08-02 Novartis Ag Substituted purinone compounds
CA2913697A1 (en) 2013-05-27 2014-12-04 Novartis Ag Imidazopyrrolidinone derivatives and their use in the treatment of disease
CA2912991A1 (en) 2013-05-28 2014-12-04 Novartis Ag Pyrazolo-pyrrolidin-4-one derivatives and their use in the treatment of disease
CA2912986A1 (en) 2013-05-28 2014-12-04 Novartis Ag Pyrazolo-pyrrolidin-4-one derivatives as bet inhibitors and their use in the treatment of disease
MX2016006667A (es) 2013-11-21 2016-07-26 Novartis Ag Derivados de pirrolo-pirrolona y su uso como inhibidores.
KR20160100975A (ko) * 2013-12-23 2016-08-24 노파르티스 아게 제약 조합물
CA2931073C (en) * 2013-12-23 2021-10-26 Novartis Ag Pharmaceutical combinations
EP3197478A4 (en) 2014-09-24 2018-05-30 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
CN107106642B (zh) 2014-09-24 2021-02-26 艾瑞朗医疗公司 拟肽大环化合物及其制剂
JP2018516844A (ja) 2015-03-20 2018-06-28 エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ペプチド模倣大環状分子およびその使用
TWI804010B (zh) 2015-08-03 2023-06-01 瑞士商諾華公司 作為血液學毒性生物標記之gdf-15
WO2017037579A1 (en) 2015-08-28 2017-03-09 Novartis Ag Mdm2 inhibitors and combinations thereof
CN108348611A (zh) * 2015-08-28 2018-07-31 诺华股份有限公司 使用pi3k抑制剂和mdm2抑制剂的联合疗法
EP3347372A4 (en) 2015-09-10 2019-09-04 Aileron Therapeutics, Inc. PEPTIDOMIMETIC MACROCYCLES AS MODULATORS OF MCL-1
KR101838687B1 (ko) 2016-01-26 2018-03-15 한국생명공학연구원 나노포어를 이용한 단백질-단백질 상호작용 저해제 스크리닝 방법
CN118436801A (zh) 2016-05-20 2024-08-06 豪夫迈·罗氏有限公司 Protac抗体缀合物及其使用方法
RU2762573C2 (ru) 2016-11-15 2021-12-21 Новартис Аг Доза и режим введения для ингибиторов взаимодействия hdm2 с p53
WO2018092064A1 (en) 2016-11-18 2018-05-24 Novartis Ag Combinations of mdm2 inhibitors and bcl-xl inhibitors
CN110381997A (zh) 2016-12-12 2019-10-25 茂体外尔公司 用于治疗和预防癌症和感染性疾病的包含病毒基因治疗和免疫检查点抑制剂的方法和组合物
US11413284B2 (en) 2017-09-12 2022-08-16 Novartis Ag Protein kinase C inhibitors for treatment of uveal melanoma
WO2019073435A1 (en) 2017-10-12 2019-04-18 Novartis Ag COMBINATIONS OF MDM2 INHIBITORS WITH ERK INHIBITORS TO TREAT CANCERS
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same
WO2024240858A1 (en) 2023-05-23 2024-11-28 Valerio Therapeutics Protac molecules directed against dna damage repair system and uses thereof

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3829420A (en) 1970-07-13 1974-08-13 Sumitomo Chemical Co 3,4-dihydro-2(1h)-quinazolinones and preparation thereof
US4099002A (en) 1970-12-23 1978-07-04 Sumitomo Chemical Company, Limited Quinazolinone derivatives and a process for production thereof
JPS4822715B1 (es) 1970-12-28 1973-07-07
JPS5427356B2 (es) 1972-03-31 1979-09-10
GB1524747A (en) 1976-05-11 1978-09-13 Ici Ltd Polypeptide
US4258187A (en) 1977-06-16 1981-03-24 E. I. Du Pont De Nemours And Company Process for preparing quinazolinone oxides
US4335127A (en) 1979-01-08 1982-06-15 Janssen Pharmaceutica, N.V. Piperidinylalkyl quinazoline compounds, composition and method of use
ATE28864T1 (de) 1982-07-23 1987-08-15 Ici Plc Amide-derivate.
GB8327256D0 (en) 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
DE3420799A1 (de) 1984-06-04 1985-12-05 Bayer Ag, 5090 Leverkusen Chromogene 4,4-diaryl-dihydrochinazolone, ihre herstellung und verwendung
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
US5010099A (en) 1989-08-11 1991-04-23 Harbor Branch Oceanographic Institution, Inc. Discodermolide compounds, compositions containing same and method of preparation and use
US5395855A (en) 1990-05-07 1995-03-07 Ciba-Geigy Corporation Hydrazones
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
AU2436792A (en) 1991-08-16 1993-03-16 Merck & Co., Inc. Quinazoline derivatives as inhibitors of hiv reverse transcriptase
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
TW225528B (es) 1992-04-03 1994-06-21 Ciba Geigy Ag
DK1975181T3 (da) 1992-10-28 2011-06-06 Genentech Inc Anvendelse af vaskulære endothelcelle-vækstfaktor-antagonister
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
DE69536015D1 (de) 1995-03-30 2009-12-10 Pfizer Prod Inc Chinazolinone Derivate
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5843901A (en) 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
EP0836605B1 (en) 1995-07-06 2002-02-06 Novartis AG Pyrrolopyrimidines and processes for the preparation thereof
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
JP3370340B2 (ja) 1996-04-12 2003-01-27 ワーナー―ランバート・コンパニー チロシンキナーゼの不可逆的阻害剤
EP0907642B1 (en) 1996-06-24 2005-11-02 Pfizer Inc. Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases
EP0958305B1 (en) 1996-07-05 2008-06-04 Cancer Research Technology Limited Inhibitions of the interaction between p53 and mdm2
AU716610B2 (en) 1996-08-30 2000-03-02 Novartis Ag Method for producing epothilones, and intermediate products obtained during the production process
DE938597T1 (de) 1996-09-06 2000-03-09 Obducat Ab Verfahren für das anisotrope ätzen von strukturen in leitende materialien
DE19638745C2 (de) 1996-09-11 2001-05-10 Schering Ag Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR)
AU4342997A (en) 1996-09-13 1998-04-02 Sugen, Inc. Use of quinazoline derivatives for the manufacture of a medicament in the reatment of hyperproliferative skin disorders
EP0837063A1 (en) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
JP4274583B2 (ja) 1996-11-18 2009-06-10 ゲゼルシャフト・フュア・ビオテクノロギッシェ・フォルシュンク・ミット・ベシュレンクテル・ハフツング（ゲー・ベー・エフ） エポチロンｃ，ｄ，ｅ及びｆ、製造と薬剤
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
GB9721069D0 (en) 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Polymeric derivatives of camptothecin
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
JP2002504540A (ja) 1998-02-25 2002-02-12 スローン−ケッタリング インスティトゥート フォア キャンサー リサーチ エポチロンの合成、その中間体およびそのアナログ
EP1107964B8 (en) 1998-08-11 2010-04-07 Novartis AG Isoquinoline derivatives with angiogenesis inhibiting activity
GB9824579D0 (en) 1998-11-10 1999-01-06 Novartis Ag Organic compounds
UA71587C2 (uk) 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
KR100851418B1 (ko) 1998-11-20 2008-08-08 코산 바이오사이언시즈, 인코포레이티드 에포틸론 및 에포틸론 유도체의 생산을 위한 재조합 방법 및 물질
EP2016953A3 (en) 1998-12-22 2009-04-15 Genentech, Inc. Vascular endothelial cell growth factor antagonists and uses thereof
JP4673977B2 (ja) 1999-03-30 2011-04-20 ノバルティス アーゲー 炎症性疾患治療用フタラジン誘導体
WO2000066560A1 (en) 1999-05-04 2000-11-09 American Home Products Corporation Quinazolinone and benzoxazine derivatives as progesterone receptor modulators
JP2001302515A (ja) 2000-04-18 2001-10-31 Sumitomo Pharmaceut Co Ltd ポリ（ａｄｐ−リボース）ポリメラーゼ阻害剤
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
TWI238824B (en) 2001-05-14 2005-09-01 Novartis Ag 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives
GB0119249D0 (en) 2001-08-07 2001-10-03 Novartis Ag Organic compounds
JP2005519915A (ja) 2002-01-18 2005-07-07 セレテック・リミテッド・ライアビリティ・カンパニー Ｅｄｇ受容体に関連する症状の処置方法
AU2003235504A1 (en) 2002-05-13 2003-11-11 3-Dimensional Pharmaceuticals, Inc. Method for cytoprotection through mdm2 and hdm2 inhibition
US7119111B2 (en) 2002-05-29 2006-10-10 Amgen, Inc. 2-oxo-1,3,4-trihydroquinazolinyl derivatives and methods of use
US20040213264A1 (en) 2003-04-25 2004-10-28 Nortel Networks Limited Service class and destination dominance traffic management
WO2005019188A1 (ja) 2003-08-22 2005-03-03 Takeda Pharmaceutical Company Limited 縮合ピリミジン誘導体およびその用途
ATE416761T1 (de) 2003-09-22 2008-12-15 Onepharm Res & Dev Gmbh Prävention und behandlung von durch entzündung ausgelöstem und/oder immunvermitteltem knochenschwund
GB0419481D0 (en) 2004-09-02 2004-10-06 Cancer Rec Tech Ltd Isoindolin-1-one derivatives
WO2006097337A2 (en) 2005-03-18 2006-09-21 Onepharm Gmbh 11β-HYDROXYSTEROID DEHYDROGENASES
US7576082B2 (en) 2005-06-24 2009-08-18 Hoffman-La Roche Inc. Oxindole derivatives
DE102006016426A1 (de) 2006-04-07 2007-10-11 Merck Patent Gmbh Neuartige Cyclobutyl-Verbindungen als Kinase-Inhibitoren
US8367699B2 (en) * 2006-09-15 2013-02-05 Nexuspharma, Inc. Tetrahydro-isoquinolines
US8440693B2 (en) * 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones

Also Published As

Publication number Publication date
PH12013500979A1 (en) 2018-04-11
US9073898B2 (en) 2015-07-07
HK1184091A1 (en) 2014-01-17
KR101561750B1 (ko) 2015-10-19
SI2640467T1 (sl) 2015-04-30
JP2013542968A (ja) 2013-11-28
IL226182A0 (en) 2013-07-31
MY160880A (en) 2017-03-31
PT2640467E (pt) 2015-03-12
US20120129871A1 (en) 2012-05-24
MA34666B1 (fr) 2013-11-02
BR112013011966A2 (pt) 2016-08-30
ZA201303155B (en) 2014-01-29
RS53770B1 (sr) 2015-06-30
CO6801719A2 (es) 2013-11-29
ME02099B (me) 2016-02-20
US8969351B2 (en) 2015-03-03
WO2012066095A1 (en) 2012-05-24
CU20120098A7 (es) 2012-10-15
SG190186A1 (en) 2013-06-28
GT201300132A (es) 2014-06-09
ES2528376T3 (es) 2015-02-09
AU2011331095A1 (en) 2013-05-30
MX336634B (es) 2016-01-26
US20130245036A1 (en) 2013-09-19
SMT201500059B (it) 2015-05-05
CY1116002T1 (el) 2017-04-26
PE20140420A1 (es) 2014-04-02
PL2640467T3 (pl) 2015-05-29
CA2816810A1 (en) 2012-05-24
DK2640467T3 (en) 2015-03-02
RU2013127661A (ru) 2014-12-27
EP2640467B1 (en) 2014-12-17
NZ610296A (en) 2014-08-29
JP5667308B2 (ja) 2015-02-12
MX2013005631A (es) 2013-07-05
ECSP13012628A (es) 2013-07-31
TWI520950B (zh) 2016-02-11
AR083905A1 (es) 2013-04-10
KR20130087572A (ko) 2013-08-06
HRP20150231T1 (xx) 2015-03-27
TW201302725A (zh) 2013-01-16
EP2640467A1 (en) 2013-09-25
AU2011331095B2 (en) 2016-03-10

Similar Documents

Publication Publication Date Title
CU20120098A7 (es) Isoquinolinonas y quinazolinonas sustituidas
NI201200111A (es) Isoquinolinonas y quinazolinonas sustituidas
DOP2013000027A (es) Derivados de tetrahidro-pirido-pirimidina
CR11757A (es) Compuestos de triazina como inhibidores mtor y quinasa pi3
UY33969A (es) Inhibidores tricíclicos fusionados dobles de las cdk 4/6 y de la flt3
PA8795701A1 (es) Derivados de isoquinolinilo e isoindolinilo como antagonistas de histamina-3
UY34261A (es) Compuestos fungicidas de 1-{2-[2-halo-4-(4-halogen-fenoxi)-fenil]-2-alcoxi-2-ciclil-etil}-1h-[1,2,4]triazol sustituidos
UY32859A (es) Compuestos y composiciones como inhibidores de cinasa de proteina
ECSP11010778A (es) Amidofenoxiindazoles útiles como inhibidores de c-met
CO6300951A2 (es) Derivados de azaciclilisoquinolinona e- isoindolinona como antagonistas de la histamina-3
CR20130087A (es) Compuestos de espiropiperidina como antagonistas del receptor orl-1
CR10060A (es) 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas
MX2011010449A (es) Derivados de oxadiazol.
ECSP089025A (es) Tratamiento de trastornos gastrointestinales con antagonistas de cgrp
CY1120661T1 (el) Ανταγωνιστες υποδοχεα 5-ητ3 σεροτονινης για χρηση στη θεραπεια των αλλοιωτικων αιθουσαιων διαταραχων
EA201291329A1 (ru) Гетероциклические соединения, их получение и их терапевтическое применение
CR20110368A (es) Compuestos de quinazolina sustituidos
CU20140103A7 (es) Compuestos de cromano sustituidos como modulares del receptor sensible al calcio
CY1115071T1 (el) Συνδυασμος ο οποιος περιεχει πακλιταξελη για τη θεραπευτικη αντιμετωπιση του καρκινου των ωοθηκων
BRPI0916657A2 (pt) pirrolidin-3-ilmetil-amina como antagonistas de orexina
ECSP13012495A (es) Compuestos de tetrahidrofuranilo disustituidos como antagonistas del receptor b1 de bradiquinina
GT200600422A (es) Derivados de carboxamida como antagonistas del receptor muscarinico
UY31840A (es) Pirrolidin amidas sustituidas como moduladores del receptor histamina h3
EA201300541A1 (ru) Производные индола
UY31924A (es) Derivados de isoquinolina e isoquinolonona bi- y policilicos sustituidos

Legal Events

Date Code Title Description
FG Grant of patent